in-PharmaTechnologist presents a round up of cGMP related warning letters issued by the FDA this week.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Stemedica and AnC Bio have formed a joint venture to manufacture stem cells for the treatment of ischemic stroke and other degenerative disorders.
New ‘chiral center’ in Belgium promises to help drug firms comply with regulatory demands for quality and accelerate registration of new compounds.
Halozyme Therapeutics will cut its workforce 25 per cent to focus on strategic alliances and development of most advanced in-house candidates.
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
Inviragen and PharmaJet have been awarded a $15.5m (€11.1m) contract by the US NIAID to develop a needle-free dengue vaccine.
Pfizer says low levels of 2,4,6 tribromoanisole were detected in seven lots of the cholesterol buster, Lipitor, that it recalled in August.
SAFC has completed the expansion of its manufacturing plant in Jerusalem, Israel, further increasing its global footprint.
Horizon Discovery has acquired Hypoxium and launched Horizon Discovery Services, to provide “a new wave” in oncology drug development.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Piramal Healthcare says expanded antibody drug conjugate (ADC) capacity will support 2011 launch of new cancer drug by US biotech partner.